改良DICE方案治疗复发难治性弥漫大B细胞淋巴瘤临床观察  

Clinical Observation of Improved DICE Regimen for Relapsed or Refractory Diffuse Large B Cell Lymphoma

作　　者：王小倩[1] 卢辉[1] 刘丽英[1] Wang Xiaoqian;Lu Hui;Liu Liying(the First people＇s Hospital of Zheng Zhou,450004,China)

机构地区：[1]郑州市第一人民医院肿瘤内科,郑州450004

出　　处：《北方药学》2018年第12期10-11,共2页Journal of North Pharmacy

摘　　要：目的:观察改良DICE方案(顺铂+依托泊苷+阿糖胞苷+甲泼尼龙)治疗复发或难治性弥漫大B细胞淋巴瘤的近期疗效及安全性。方法:21例经系统治疗复发或进展的弥漫大B细胞淋巴瘤采用改良DICE方案化疗,2周期后观察近期疗效及不良反应。结果:21例患者均可评价疗效,其中完全缓解(CR)5例,部分缓解(PR)8例,疾病稳定(SD)6例,疾病进展(PD)2例,客观有效率为61.90%,临床获益率90.48%。化疗不良反应主要为消化道反应和骨髓抑制,无化疗相关性死亡病例发生。结论:改良DICE方案可作为复发难治性弥漫大B细胞淋巴瘤的二线解救方案。Objective：To observe the recent efficacy and safety of improved DICE（Cisplatin, etoposide, cytarabine, and methylprednisolone）regimen in the treatment of relapsed or refractory diffuse large B cell lymphoma. Methods： Twenty-one patients with diffuse large B cell lymphoma who had relapsed or progressed after systemic therapy were treated with improved DICE regimen. The recent efficacy and toxicities were observed after two cycles of chemotherapy. Results： All of the 21 patients were evaluated for efficacy.5 patients achieved complete remission（CR）,8 cases partial remission（PR）,6 cases stable disease（SD）,2 cases progressive disease（PD）. The overall response rate was 61.90%,the clinical benefit rate was 90.48%. The main adverse reactions were gastrointestinal reactions and myelosuppression,No chemotherapy-related death was observed. Conclusion： The improved DICE regimen can be used as a second-line rescue strategy for relapsed or refractory diffuse large B cell lymphoma.

关 键 词：非霍奇金淋巴瘤 弥漫大B细胞淋巴瘤 DICE方案 复发 难治 

分 类 号：R730.263[医药卫生—肿瘤]